Moderna, Inc. $MRNA Stock Holdings Lifted by Candriam S.C.A.

Candriam S.C.A. lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 24.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 384,828 shares of the company’s stock after acquiring an additional 75,632 shares during the quarter. Candriam S.C.A.’s holdings in Moderna were worth $74,377,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Ethic Inc. raised its holdings in shares of Moderna by 23.6% during the 3rd quarter. Ethic Inc. now owns 19,394 shares of the company’s stock valued at $3,735,000 after buying an additional 3,700 shares during the period. Parallel Advisors LLC lifted its position in Moderna by 8.8% during the 3rd quarter. Parallel Advisors LLC now owns 5,082 shares of the company’s stock worth $979,000 after acquiring an additional 410 shares in the last quarter. Abacus Wealth Partners LLC purchased a new position in Moderna in the 3rd quarter worth approximately $259,000. Plancorp LLC purchased a new position in Moderna in the 3rd quarter worth approximately $210,000. Finally, May Hill Capital LLC purchased a new position in Moderna in the 3rd quarter worth approximately $238,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Analysts Set New Price Targets

Several brokerages have issued reports on MRNA. Singular Research raised shares of Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Citigroup reissued a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Friday, August 28th. Bank of America raised their price target on shares of Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, October 9th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $107.10.

Moderna Stock Up 5.3%

NASDAQ:MRNA opened at $254.19 on Friday. The company has a market capitalization of $101.48 billion, a price-to-earnings ratio of -35.80 and a beta of 1.16. Moderna, Inc. has a one year low of $22.28 and a one year high of $267.50. The stock has a 50-day simple moving average of $191.85 and a 200 day simple moving average of $91.51. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. The firm’s revenue for the quarter was up 29.2% compared to the same quarter last year. Sell-side analysts predict that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.